AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21593283
Drug: Microdose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose of celiprolol (97.5 µg)
Trial: 18073779
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g per day PS-enriched spread
Trial: 17581778
Drug: Beta-blocker treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker treatment withdrawn
Trial: 17581778
Drug: Beta-blocker dose
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker dose reduction
Trial: 17581778
Drug: Beta-blocker maintained
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker maintained on the same dose
Trial: 15037890
Drug: Latanoprost/timolol maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/timolol maleate fixed combination (LTFC) given once daily
Trial: 15037890
Drug: Brimonidine twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine twice daily and latanoprost once daily
Trial: 11418458
Drug: VBMCP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBMCP with high-dose cyclophosphamide
Trial: 11418458
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (VBMCP with interferon, high-dose cyclophosphamide, or VBMCP alone)
Trial: 9249104
Drug: Midazolam premedication
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam premedication (0.04 mg/kg)
Trial: 3541714
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg of caffeine in solution orally
Trial: 26756554
Drug: 15 intra-detrusor
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 intra-detrusor injections of Dysport 750 U
Trial: 26756554
Drug: 30 intra-detrusor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 intra-detrusor injections of Dysport 750 U
Trial: 26756554
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 15 injections
Trial: 26756554
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 30 injections
Trial: 26756554
Drug: Dysport groups
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dysport groups (both 15 and 30 injections)
Trial: 19735512
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration HA fillers (24 mg/mL) - Juvéderm Ultra, Ultra Plus, and 30
Trial: 19735512
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration HA fillers (5.5 mg/mL) - Hylaform, Hylaform Plus, and Captique
Trial: 11453908
Drug: Dithranol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol 2% cream + Clobetasol-17-propionate 0.05% ointment
Trial: 11453908
Drug: Dithranol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol 2% cream + Vehicle
Trial: 1417691
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and behavioral treatments
Trial: 31177856
Drug: Fremanezumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fremanezumab (subcutaneous injection, IgG2Δa)
Trial: 27348908
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at acupoints on the axillary nerve distribution (Jianjing, Jianzhen, Jianliao, Jianyu, Quyuan, Tianzong, and trigger points in the scapular region) with Hegu needling and electric stimulation (continuous wave, 1Hz) for 30 min, once every two days for 10 treatments.
Trial: 27348908
Drug: Regular acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular acupuncture at Dazhui, Tianzhu, Houxi, and cervical Jiaji (EX-B 2) with electric stimulation at cervical Jiaji (EX-B 2) for 30 min, once every two days for 10 treatments.
Trial: 25019969
Drug: Split-dose sodium
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose sodium picosulfate plus magnesium citrate (PMC)
Trial: 25019969
Drug: Standard-dose sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose sodium picosulfate plus magnesium citrate (PMC)
Trial: 17980364
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and orlistat (120 mg, 3 times per day) for 24 weeks
Trial: 12114416
Drug: SAM486A at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM486A at a maximum tolerated dose (MTD) of 102.4 mg/m2/day
Trial: 10399774
Drug: 0.05 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/day of 17 beta-estradiol via skin patch
Trial: 1574968
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion 1 mg kg‐1 h‐1 preceded by a 1 mg kg‐1 bolus
Trial: 1574968
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 micrograms kg‐1 and diazepam 0.05 mg kg‐1
Trial: 4028905
Drug: Ethanol 0.4
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.4 g/kg body weight
Trial: 4028905
Drug: Ethanol 0.6
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.6 g/kg body weight
Trial: 4028905
Drug: Ethanol 0.8
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.8 g/kg body weight
Trial: 26786710
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid plus subcutaneous injections of carbon dioxide
Trial: 19049337
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/d for 12 months after teriparatide)
Trial: 19049337
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment (after teriparatide)
Trial: 17097942
Drug: Celsior solution
RxNorm normalized name: Fraxinus excelsior leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celsior solution (CS), n = 40
Trial: 17097942
Drug: University of
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: University of Wisconsin solution (UW), n = 40
Trial: 9417503
Drug: Sodium selenite
RxNorm normalized name: Sodium selenite
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sodium selenite in combination with intensive decongestive physical therapy
Trial: 8256080
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg propranolol
Trial: 8256080
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg atenolol
Trial: 29555665
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with 2300 mg Na
Trial: 2187668
Drug: Urokinase administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase administered intravenously as a bolus before hospital admission (group I, n = 40)
Trial: 2187668
Drug: Urokinase administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase administered intravenously as a bolus after hospital admission (group II, n = 38)
Trial: 25765536
Drug: Topical tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tryptophan
Trial: 21246077
Drug: Sandblasted, silica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 20 wt% silica sols, and then silane coupling agent applied (Group Al20C)
Trial: 21246077
Drug: Sandblasted, silica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 30 wt% silica sols, and then silane coupling agent applied (Group Al30C)
Trial: 21246077
Drug: Sandblasted, silica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 40 wt% silica sols, and then silane coupling agent applied (Group Al40C)
Trial: 21246077
Drug: Sandblasted +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandblasted + silane coupling agent applied (Group AlC)
Trial: 17605780
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg, n = 43) every six hours for a total of four doses on the day preceding extubation
Trial: 17605780
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline, n = 43) every six hours for a total of four doses on the day preceding extubation
Trial: 17605780
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg, n = 43)
Trial: 11795455
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 32 mg per day for 6 months
Trial: 7986245
Drug: Folsan tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folsan tablet (5 mg folic acid)
Trial: 7986245
Drug: Folsan injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folsan injection solution (reference preparation B)
Trial: 2645385
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: discontinue therapy
Trial: 2645385
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: reinduction for 4 weeks, then discontinue therapy
Trial: 2645385
Drug: Regimen C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C: continue maintenance therapy for 2 more years, then discontinue
Trial: 2645385
Drug: Boys randomized
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boys randomized to discontinue therapy
Trial: 31574157
Drug: Dural Sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dural Sealant Patch (DSP)
Trial: 20381654
Drug: NT-pro-BNP level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-pro-BNP level > or = 260 pg/ml
Trial: 16647139
Drug: Personality measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personality measures before and after treatment
Trial: 14563572
Drug: Ad5FGF‐4 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5FGF‐4 gene therapy
Trial: 10821451
Drug: Pooled results
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled results from both trials; treatment group from both trials.
Trial: 8888383
Drug: Nicotine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (administered subcutaneously or by cigarette smoking)
Trial: 8888383
Drug: Amphetamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (5 mg administered 90 min before testing)
Trial: 1892303
Drug: formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol 12 micrograms twice a day
Trial: 1892303
Drug: albuterol 200
RxNorm normalized name: ALBUTEROL 200MCG CAP,INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albuterol 200 micrograms four times a day
Trial: 29388929
Drug: Vermel electrophoresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vermel electrophoresis with 1% sodium bromide solution
Trial: 25362228
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) dalteparin
Trial: 14749693
Drug: Lanreotide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 100 microg/h infusion for 8 hours
Trial: 14749693
Drug: Lanreotide 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 800 microg bolus injection
Trial: 11679509
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg on days 5-9)
Trial: 9129858
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (specific dosage and duration not mentioned)
Trial: 9129858
Drug: Randomized recommendation
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized recommendation to use or not use hormone therapy
Trial: 3591257
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (225-375 micrograms) + diazepam (5-15 mg)
Trial: 3591257
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg the night before and 300 mg in the morning) + diazepam
Trial: 20874659
Drug: Sex hormone-binding
RxNorm normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone-binding globulin
Trial: 24336948
Drug: Pacemaker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker therapy in patients with negative tilt test (TT-), 26 patients
Trial: 24336948
Drug: Pacemaker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacemaker therapy in patients with positive tilt test (TT+), 26 patients
Trial: 17353402
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) solution
Trial: 11528550
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment with initial leukaemic blood blast count < 1000 blasts/microliter
Trial: 11528550
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment with initial leukaemic blood blast count >= 1000 blasts/microliter
Trial: 11528550
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with < 1000 blasts/microliter on day eight of treatment but increasing blast count
Trial: 7607785
Drug: Mazindol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (0.5 mg, three tablets per day for three months)
Trial: 7607785
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three tablets per day for three months)
Trial: 29739354
Drug: Icodextrin solution
RxNorm normalized name: icodextrin Irrigation Solution
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icodextrin solution (ICO)
Trial: 29739354
Drug: Glucose-based solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based solution (GLU)
Trial: 24373856
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical fluoride treatment (active caries)
Trial: 23593205
Drug: Sodium thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium thiosulfate (STS) 10 mmol twice a day for 7 days
Trial: 19052406
Drug: Calcipotriol 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 0.005% ointment applied twice daily
Trial: 19052406
Drug: Tazarotene 0.05%
RxNorm normalized name: TAZAROTENE 0.05% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.05% gel applied once daily
Trial: 19052406
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel applied once daily
Trial: 11673585
Drug: 8.0 mg
RxNorm normalized name: KAOLIN 8.0 mg in 100 mL ORAL LIQUID [Diarrhea Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.0 mg albuterol twice daily
Trial: 11673585
Drug: 16.0 mg
RxNorm normalized name: MENTHOL 16.0 mg ORAL LOZENGE [COOL RELIEF LEMON FROST ORAL ANESTHETIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.0 mg albuterol twice daily
Trial: 30877066
Drug: Lycium barbarum
RxNorm normalized name: LYCIUM BARBARUM FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycium barbarum (LB) supplement
Trial: 24128861
Drug: Fludarabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine plus cyclophosphamide (FC) chemotherapy
Trial: 22506139
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and NMES
Trial: 22506139
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy only
Trial: 19692530
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry juice (240 mL twice daily for 14 days)
Trial: 19692530
Drug: Placebo (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (240 mL twice daily for 14 days)
Trial: 16508640
Drug: CHOP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisolone 100 mg)
Trial: 16508640
Drug: PMitCEBO (mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMitCEBO (mitoxantrone 7 mg/m², cyclophosphamide 300 mg/m², etoposide 150 mg/m², vincristine 1.4 mg/m², bleomycin 10 mg/m², prednisolone 50 mg)
Trial: 11020593
Drug: Baseline misconceptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline misconceptions (e.g., washing genitals after sex, urinating after sex, douching, use of oral contraceptives)
Trial: 9068812
Drug: Killed Mycobacterium
RxNorm normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed Mycobacterium vaccae as immunotherapy
Trial: 3096133
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the arm
Trial: 3096133
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the chest
Trial: 3096133
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (12.5 to 50 mg) applied to the thigh
Trial: 19675365
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol dose
Trial: 19675365
Drug: High alcohol
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High alcohol dose
Trial: 17343006
Drug: Fructus Bruceae
RxNorm normalized name: Brucea javanica fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructus Bruceae oil emulsion (FBE) combined with chemotherapy (GP regimen)
Trial: 17343006
Drug: Chemotherapy (GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (GP regimen) only
Trial: 15295219
Drug: Palivizumab 5
RxNorm normalized name: PALIVIZUMAB 50MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab 5 mg/kg
Trial: 3382595
Drug: Metoclopramide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide with oral controlled release morphine
Trial: 3382595
Drug: Oral controlled
RxNorm normalized name: Afeditab CR Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral controlled release morphine alone
Trial: 30900194
Drug: Animal Assisted
RxNorm normalized name: animals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal Assisted Therapy (AAT) with dogs
Trial: 22964343
Drug: Immediate Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate Intervention Group (IIG) - Relaxation therapy days 3-6
Trial: 22964343
Drug: Delayed Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed Intervention Group (DIG) - Relaxation therapy days 6-9
Trial: 17404163
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg/ramipril 5 mg
Trial: 17404163
Drug: Verapamil 180
RxNorm normalized name: verapamil 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 180 mg/trandolapril 2 mg
Trial: 17404163
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate 95 mg/hydrochlorothiazide 12.5 mg
Trial: 7554709
Drug: Mofegiline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mofegiline (single oral doses up to 48 mg)
Trial: 7554709
Drug: Mofegiline (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mofegiline (daily doses for 28 days up to 24 mg)
Trial: 7554709
Drug: Mofegiline (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mofegiline (doses up to 24 mg)